AZD6621

AZD6621 is a T-cell engager developed by AstraZeneca. Its target is CD3 (the sponsor names STEAP2 x CD3 x CD8). The sponsor states: AZD6621 is a T-cell-engaging antibody that targets STEAP2, CD3 and CD8, designed to engage T cells against STEAP2-expressing prostate cancer cells (ACTIVATED-4-PC study). ClinicalTrials.gov describes the intervention as: A T Cell-engaging Antibody that targets STEAP2, CD3, and CD8. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in prostate cancer. The largest, NCT07192614, plans to enrol 52 participants with primary completion expected 2029-03-29. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.